Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed aft the telemedicine level came to an statement with Novo Nordisk (NYSE: NVO) to merchantability the drugmaker's fashionable GLP-1 value nonaccomplishment drugs. The question connected galore investors' minds is whether it is excessively precocious to bargain the stock. Let's instrumentality a person look.

Hims & Hers and Novo Nordisk person had a tumultuous narration implicit the past mates of years. The companies formed a short-lived commercialized concern past year, lone for Novo Nordisk to locomotion away, saying that Hims had not lived up to its extremity of the bargain by continuing to illegally merchantability compounded versions of its drugs nether the guise of personalization.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Hims had legally been capable to merchantability the compounded drugs erstwhile semaglutide, the main constituent successful Novo's Wegovy and Ozempic drugs, was successful shortage. However, the FDA declared the cause was nary longer successful shortage successful February 2025. Hims had agelong contended that it had the ineligible close to merchantability personalized versions of these drugs and that it was champion for patients. At the clip of the breakup, the institution said that Novo Nordisk was pressuring it to merchantability the branded mentation of its drugs and that it would not beryllium "strong-armed."

The 2 companies aboriginal entered talks to merchantability Wegovy past November, arsenic Novo Nordisk rolled retired a caller pill signifier of the drug. However, a woody ne'er came to fruition, and Novo Nordisk sued Hims successful February of this twelvemonth aft the telehealth institution announced plans to merchantability a lower-cost mentation of the Wegovy pill. While Hims argued its personalized dose mentation could assistance amended negociate broadside effects, the FDA started pressuring compounding cause companies implicit value nonaccomplishment drugs, starring Hims to discontinue selling its copycat mentation of the Wegovy pill.

As such, the caller woody with Novo Nordisk came arsenic rather a astonishment to investors. Hims volition present connection Ozempic injections and Wegovy pills connected its platform. It volition inactive supply immoderate personalized compound semaglutide drugs to patients erstwhile medically necessary, but it volition nary longer advertise this enactment connected its level oregon successful its marketing. Meanwhile, the suit volition beryllium dropped.

The statement with Novo Nordisk and the extremity of the suit region 1 of Hims's biggest overhangs. The information that Novo Nordisk was consenting to spell backmost to the institution besides illustrates the scope of Hims' platform. This should assistance thrust growth, though it volition travel astatine a little gross margin.